GlassScriptPhysician profile
Raveena Singh
NPI 1881444792
$674.37
in general payments reported to CMS, 2019-2025
11 companies · $62.44 in 2025
The $62.44 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $612 · 2025: $62.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $164.66 | 2024-2025 | |
| Novo Nordisk INC | $147.96 | 2024-2025 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $57.49 | 2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $54.98 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $50.94 | 2024 | Airsupra |
| Exact Sciences Corporation | $46.70 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $44.82 | 2024 | |
| Lilly USA, LLC | $31.49 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.39 | 2024 | Jardiance |
| Amgen INC. | $28.05 | 2024 | Repatha, Otezla |
| Tactile Systems Technology INC | $16.89 | 2024 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raveena Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.